Literature DB >> 15019674

Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung.

Adnan Sayar1, Akif Turna, Ali Kiliçgün, Okan Solak, Nur Urer, Atilla Gürses.   

Abstract

OBJECTIVES: The surgical outcome of pathologic N1 disease in resectable non-small cell lung carcinoma (NSCLC) is controversial. The prognosis of the patients with multiple/bulky N2 disease was invariably dismal. However, the prognostic significance of tumor involvement in more than one hilar or intralobar lymph node station has not been fully described.
METHODS: From 1996 to 2002, 181 patients with NSCLC had complete resection. Four levels of N1 nodes and N2 nodes were identified using the new regional lymph node classification for lung cancer staging. There were 67 patients (37%) with no nodal disease (N0), 43 patients (24%) with N1 and 71 patients (39%) with N2 disease. The N1 subgroup cases were reviewed. The prognostic significances of single and multiple N1 diseases were tested.
RESULTS: The cumulative postoperative survival at 3 and 5 years was 57 and 29%, respectively. The survival associated with single-station N1 disease was significantly better than that of multiple-station N1 disease (45 vs 32% at 5 years; P=0.03). Five-year survival was similar in patients with multiple N1 disease and patients with single-station N2 involvement (32 vs 31% at 5 years; P=0.84). However, no patient survived when tumor was detected in more than one mediastinal station (i.e. multiple N2 disease).
CONCLUSIONS: It was suggested that N1 disease is a compound of two subgroups: one involving in one node and the other (multiple N1 disease) in which the postoperative prognosis was not statistically different from that of N2 disease.

Entities:  

Mesh:

Year:  2004        PMID: 15019674     DOI: 10.1016/j.ejcts.2003.12.005

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Early recurrence of completely resected N2-positive non-small-cell lung cancer.

Authors:  Takuma Tsukioka; Noritoshi Nishiyama; Takashi Iwata; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Kiyotoshi Inoue; Shigefumi Suehiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-03

2.  Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer.

Authors:  Juan P Wisnivesky; Jacqueline Arciniega; Grace Mhango; John Mandeli; Ethan A Halm
Journal:  Thorax       Date:  2010-12-02       Impact factor: 9.139

3.  Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer.

Authors:  Sirisha Jonnalagadda; Jacqueline Arcinega; Cardinale Smith; Juan P Wisnivesky
Journal:  Cancer       Date:  2011-03-30       Impact factor: 6.860

4.  The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer.

Authors:  Sirisha Jonnalagadda; Cardinale Smith; Grace Mhango; Juan P Wisnivesky
Journal:  Chest       Date:  2011-02-03       Impact factor: 9.410

5.  Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?

Authors:  Ali Kilicgun; Ozgur Tanriverdi; Akif Turna; Muzaffer Metin; Adnan Sayar; Okan Solak; Nur Urer; Atilla Gurses
Journal:  Med Oncol       Date:  2011-03-24       Impact factor: 3.064

6.  The role of segmental nodes in the pathological staging of non-small cell lung cancer.

Authors:  Zhen-xuan Li; Hong Yang; Ke-lin She; Ming-xing Zhang; Han-qing Xie; Peng Lin; Lan-jun Zhang; Xiao-dong Li
Journal:  J Cardiothorac Surg       Date:  2013-12-08       Impact factor: 1.637

7.  Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.

Authors:  Melissa A L Vyfhuis; Neha Bhooshan; Whitney M Burrows; Michelle Turner; Mohan Suntharalingam; James Donahue; Elizabeth M Nichols; Josephine Feliciano; Søren M Bentzen; Shahed Badiyan; Shamus R Carr; Joseph Friedberg; Charles B Simone; Martin J Edelman; Steven J Feigenberg; Pranshu Mohindra
Journal:  Adv Radiat Oncol       Date:  2017-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.